Literature DB >> 16014913

Humoral immune response recognizes a complex set of epitopes on human papillomavirus type 6 l1 capsomers.

Johnnie J Orozco1, Joseph J Carter, Laura A Koutsky, Denise A Galloway.   

Abstract

Although epitope mapping has identified residues on the human papillomavirus (HPV) major capsid protein (L1) that are important for binding mouse monoclonal antibodies, epitopes recognized by human antibodies are not known. To map epitopes on HPV type 6 (HPV6) L1, surface-exposed loops were mutated to the corresponding sequence of HPV11 L1. HPV6 L1 capsomers had one to six regions mutated, including the BC, DE, EF, FG, and HI loops and the 139 C-terminal residues. After verifying proper conformation, hybrid capsomers were used in enzyme-linked immunosorbent assays with 36 HPV6-seropositive sera from women enrolled in a study of incident HPV infection. Twelve sera were HPV6 specific, while the remainder reacted with both HPV6 and HPV11 L1. By preadsorption studies, 6/11 of these sera were shown to be cross-reactive. Among the HPV6-specific sera there was no immunodominant epitope recognized by all sera. Six of the 12 sera recognized epitopes that contained residues from combinations of the BC, DE, and FG loops, one serum recognized an epitope that consisted partially of the C-terminal arm, and three sera recognized complex epitopes to which reactivity was eliminated by switching all five loops. Reactivity in two sera was not eliminated even with all six regions swapped. The patterns of epitope recognition did not change over time in women whose sera were examined 9 years after their first-seropositive visit.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16014913      PMCID: PMC1181614          DOI: 10.1128/JVI.79.15.9503-9514.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  54 in total

1.  Conserved features in papillomavirus and polyomavirus capsids.

Authors:  D M Belnap; N H Olson; N M Cladel; W W Newcomb; J C Brown; J W Kreider; N D Christensen; T S Baker
Journal:  J Mol Biol       Date:  1996-06-07       Impact factor: 5.469

2.  Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes.

Authors:  N D Christensen; R Kirnbauer; J T Schiller; S J Ghim; R Schlegel; A B Jenson; J W Kreider
Journal:  Virology       Date:  1994-11-15       Impact factor: 3.616

3.  Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization.

Authors:  R Kirnbauer; L M Chandrachud; B W O'Neil; E R Wagner; G J Grindlay; A Armstrong; G M McGarvie; J T Schiller; D R Lowy; M S Campo
Journal:  Virology       Date:  1996-05-01       Impact factor: 3.616

4.  Two amino acid residues confer type specificity to a neutralizing, conformationally dependent epitope on human papillomavirus type 11.

Authors:  S W Ludmerer; D Benincasa; G E Mark
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

5.  Serum IgG, IgM, and IgA reactivity to human papillomavirus types 11 and 6 virus-like particles in different gynecologic patient groups.

Authors:  K Heim; N D Christensen; R Hoepfl; B Wartusch; G Pinzger; A Zeimet; P Baumgartner; J W Kreider; O Dapunt
Journal:  J Infect Dis       Date:  1995-08       Impact factor: 5.226

6.  Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas.

Authors:  J A Suzich; S J Ghim; F J Palmer-Hill; W I White; J K Tamura; J A Bell; J A Newsome; A B Jenson; R Schlegel
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-05       Impact factor: 11.205

7.  Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation.

Authors:  K U Jansen; M Rosolowsky; L D Schultz; H Z Markus; J C Cook; J J Donnelly; D Martinez; R W Ellis; A R Shaw
Journal:  Vaccine       Date:  1995-11       Impact factor: 3.641

8.  Sequence determination of human papillomavirus type 6a and assembly of virus-like particles in Saccharomyces cerevisiae.

Authors:  K J Hofmann; J C Cook; J G Joyce; D R Brown; L D Schultz; H A George; M Rosolowsky; K H Fife; K U Jansen
Journal:  Virology       Date:  1995-06-01       Impact factor: 3.616

9.  Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection.

Authors:  F Breitburd; R Kirnbauer; N L Hubbert; B Nonnenmacher; C Trin-Dinh-Desmarquet; G Orth; J T Schiller; D R Lowy
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

10.  A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16.

Authors:  R Kirnbauer; N L Hubbert; C M Wheeler; T M Becker; D R Lowy; J T Schiller
Journal:  J Natl Cancer Inst       Date:  1994-04-06       Impact factor: 13.506

View more
  13 in total

Review 1.  Lessons learned from successful human vaccines: Delineating key epitopes by dissecting the capsid proteins.

Authors:  Xiao Zhang; Lu Xin; Shaowei Li; Mujin Fang; Jun Zhang; Ningshao Xia; Qinjian Zhao
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Identification of neutralizing conformational epitopes on the human papillomavirus type 31 major capsid protein and functional implications.

Authors:  Maxime J J Fleury; Antoine Touzé; Marie-Christine Maurel; Thierry Moreau; Pierre Coursaget
Journal:  Protein Sci       Date:  2009-07       Impact factor: 6.725

Review 3.  Development of a human papillomavirus competitive luminex immunoassay for 9 HPV types.

Authors:  Christine Roberts; Tina Green; Erica Hess; Katie Matys; Martha J Brown; Richard M Haupt; Alain Luxembourg; Scott Vuocolo; Alfred Saah; Joseph Antonello
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 4.  The papillomavirus major capsid protein L1.

Authors:  Christopher B Buck; Patricia M Day; Benes L Trus
Journal:  Virology       Date:  2013-06-22       Impact factor: 3.616

Review 5.  Paradigm shifting vaccines: prophylactic vaccines against latent varicella-zoster virus infection and against HPV-associated cancer.

Authors:  Ian H Frazer; Myron J Levin
Journal:  Curr Opin Virol       Date:  2011-10       Impact factor: 7.090

6.  Identification of human papillomavirus type 16 L1 surface loops required for neutralization by human sera.

Authors:  Joseph J Carter; Greg C Wipf; Margaret M Madeleine; Stephen M Schwartz; Laura A Koutsky; Denise A Galloway
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

7.  Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibition.

Authors:  Patricia M Day; Cynthia D Thompson; Christopher B Buck; Yuk-Ying S Pang; Douglas R Lowy; John T Schiller
Journal:  J Virol       Date:  2007-06-06       Impact factor: 5.103

8.  Characterization of neutralizing epitopes within the major capsid protein of human papillomavirus type 33.

Authors:  Stefanie D Roth; Martin Sapp; Rolf E Streeck; Hans-Christoph Selinka
Journal:  Virol J       Date:  2006-10-02       Impact factor: 4.099

9.  Amino acid sequence diversity of the major human papillomavirus capsid protein: implications for current and next generation vaccines.

Authors:  Amina I Ahmed; Sara L Bissett; Simon Beddows
Journal:  Infect Genet Evol       Date:  2013-05-27       Impact factor: 3.342

10.  Risk of squamous cell skin cancer after organ transplant associated with antibodies to cutaneous papillomaviruses, polyomaviruses, and TMC6/8 (EVER1/2) variants.

Authors:  Margaret M Madeleine; Joseph J Carter; Lisa G Johnson; Gregory C Wipf; Connie Davis; Daniel Berg; Karen Nelson; Janet R Daling; Stephen M Schwartz; Denise A Galloway
Journal:  Cancer Med       Date:  2014-06-10       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.